Welcome to the Institute of Clinical Research

Welcome to the Institute of Clinical Research

About Us

The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.  

For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community.  For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.

It is the membership that makes the Institute.

How does it all work ?

The Institute of Clinical Research is you, the Membership governed by the Articles of Memorandum drawn up by the founding members.

The Board is made up of members who give their time freely to guide the future direction of the ICR.

The ICR Secretariat is the administrative arm of the Institute, its primary focus is to ensure that the wishes of the Board and Membership are carried out and to see to the day to day tasks that any membership organisation generates.

  

Our Mission

The ICR exists to support our members through all stages of their careers. We do this, in part, by:

  • Defining and refining standards for our profession
  • Providing a forum for discussion of key issues impacting clinical research
  • Promoting good relations with other healthcare related groups 
  • Providing opportunities for learning and development to enhance professional competence 
  • Enhancing public confidence and understanding of clinical research

 

Current News

MHRA authorises Vumerity for multiple sclerosis patients

By ICR Secretariat / 25/11/2021 02:55 PM

The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for relapsing-remitting multiple sclerosis.

Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?

By ICR Secretariat / 25/11/2021 02:54 PM

Pharma companies vying for a piece of the lucrative migraine market have gone all-in on marketing. They've turned to Olympic athletes and Hollywood st…

FDA, aiming to curb another COVID-19 surge, clears Pfizer, Moderna boosters for all adults

By ICR Secretariat / 25/11/2021 02:47 PM

The Food and Drug Administration on Friday authorized COVID-19 booster shots for all vaccinated Americans over 18, a move that's meant to stem a rise …


2021's Fiercest Women in Life Sciences

By ICR Secretariat / 22/11/2021 10:34 AM

“It took a village to make me.” These words spoken by WeiQing Zhou, who is the cofounder of two biotechs, could apply to almost any of the women on th…

J&J, world's largest drugmaker, plans to split in two

By ICR Secretariat / 22/11/2021 10:31 AM

Johnson & Johnson, the world's largest drugmaker and one of its oldest, is splitting in two in a major corporate shake-up that's meant to boost th…

NICE ‘no’ for BioMarin’s Vimizin

By ICR Secretariat / 22/11/2021 10:29 AM

The National Institute for Health and Care Excellence (NICE) has published draft guidance in which it has decided not to recommend BioMarin’s rare dis…


Ethics & GCP Forum 14th December OPEN FOR BOOKINGS!

By ICR Secretariat / 11/11/2021 03:52 PM

We are excited to announce that our Ethics & GCP Forum will take place online via Zoom on Tuesday 14th December 2021. 

See here for the draft agen…

NICE issues draft recommendation for new kidney disease treatment

By ICR Secretariat / 11/11/2021 02:39 PM

NICE has issued a draft recommendation for Forxiga (dapagliflozin) for the treatment of adults with chronic kidney disease. This preliminary recommend…

GlaxoSmithKline's novel anemia drug succeeds where AstraZeneca-FibroGen, Akebia failed

By ICR Secretariat / 11/11/2021 02:37 PM

After the FDA’s resounding rejection for AstraZeneca and FibroGen’s roxadustat, attention on novel oral anemia therapies has shifted to later players.…


Pfizer’s COVID-19 pill cuts hospitalisation/death risk by 89%

By ICR Secretariat / 11/11/2021 02:36 PM

Pfizer has announced that its investigational COVID-19 antiviral medicine cut the risk of hospitalisation or death by 89% in an interim analysis of th…

AbbVie's Vraylar turns in mixed results in depression, but pharma decides to file for approval anyway

By ICR Secretariat / 04/11/2021 01:59 PM

Vraylar, used as an adjunctive treatment to existing antidepressants, significantly outdid placebo in a phase 3 trial, AbbVie unveiled Friday. But add…

Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial

By ICR Secretariat / 04/11/2021 01:57 PM

Gilead Sciences and MSD – known as Merck in the US and Canada – have announced a clinical trial collaboration to test a combination of Gilead’s Trodel…


Merck sees up to $7B in coming sales of coronavirus pill

By ICR Secretariat / 04/11/2021 01:56 PM

  • Merck & Co. executives forecast between $5 billion and $7 billion in sales of the company's COVID-19 pill through the end of 2022, assuming an ex…

Psychoactive compound to advance research in treatment of depressive disorders

By ICR Secretariat / 28/10/2021 04:01 PM

FSD Pharma has signed an agreement with Covar Pharmaceuticals to support the development of Lucid-PSYCH, a psychoactive compound potentially viable fo…

Pfizer, in a first, shows booster shot strengthens COVID-19 protection in large study

By ICR Secretariat / 28/10/2021 03:59 PM

  • A third dose of Pfizer and BioNTech's coronavirus vaccine restored the shot's strong protection against COVID-19 in a large randomized trial, the com…


UK doctors: Renewed COVID response is urgent

By ICR Secretariat / 28/10/2021 03:56 PM

Health Secretary Sajid Javid’s statement that 179 COVID deaths a day are “mercifully low” has sparked criticism from COVID-19 experts. Government stat…

Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’

By ICR Secretariat / 21/10/2021 12:15 PM

Over the last year, the Johnson & Johnson COVID-19 vaccine has been commonly referred to as a single-shot alternative to the two-dose regimens of …

FDA clears Keytruda for first-line cervical cancer

By ICR Secretariat / 21/10/2021 12:01 PM

MSD’s PD-1 inhibitor Keytruda (pembrolizumab) has received approval from the US Food and Drug Administration (FDA) for the first-line treatment of cer…




Events and Courses

Effective Project Management for Clinical Trials (3 Days ) K42

This practical course provides delegates with basic project management techniques that can be applied to clinical trial project management. Learning i...


The ICR Ethics & GCP Forum EGCP

The ICR Ethics and GCP Forum provides an excellent opportunity to:  Keep up to date with current ethical and clinical r...


Current Jobs